爱博医疗收盘下跌1.13%，滚动市盈率49.18倍，总市值190.42亿元

Company Overview - Aibo Medical focuses on the research, production, and sales of ophthalmic medical devices, primarily targeting cataracts and refractive errors [2] - The company is recognized as the first high-end refractive artificial lens manufacturer in China and is one of the major manufacturers of foldable artificial lenses [2] - Aibo Medical has received multiple awards and recognitions, including the Beijing Science and Technology Second Prize and the "Top Ten Achievements in Chinese Ophthalmology" [2] Financial Performance - For the third quarter of 2024, Aibo Medical reported a revenue of 1.075 billion yuan, representing a year-on-year increase of 60.94% [2] - The net profit for the same period was 318 million yuan, showing a year-on-year growth of 26.04% [2] - The sales gross margin stood at 67.61% [2] Market Position - As of April 3, Aibo Medical's stock closed at 100.46 yuan, with a rolling price-to-earnings (PE) ratio of 49.18 times [1] - The average PE ratio in the medical device industry is 46.48 times, with a median of 31.96 times, placing Aibo Medical at the 89th position in the industry ranking [1][3] - The total market capitalization of Aibo Medical is 19.042 billion yuan [1]